EpiCept to Report Second Quarter 2012 Operating and Financial Results on August 8, 2012

  EpiCept to Report Second Quarter 2012 Operating and Financial Results on
  August 8, 2012

Business Wire

TARRYTOWN, N.Y. -- August 02, 2012

Regulatory News:

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that it will host a conference call to discuss second quarter 2012
operating and financial results on Wednesday, August 8, 2012 at 9:00 a.m.
Eastern time. The call will follow the release of these financial results
earlier in the day at 12:01 a.m. Eastern time.

To participate in the live call and be able to participate in the question and
answer session, please dial from the U.S. and Canada (877) 809-8594 or from
international locations (706) 758-9407 (please reference access code 17527052)
prior to the start of the conference. The conference call will also be
broadcast live in listen-only mode on the Internet and may be accessed at
www.epicept.com. The webcast will be archived for 90 days.

A telephone replay of the call will be available for seven days by dialing
from the U.S. and Canada (855) 859-2056 or from international locations (404)
537-3406 (please reference reservation number 17527052).

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical
products for the treatment of pain and cancer. The Company's pain portfolio
includes AmiKet™, a prescription topical analgesic cream in late-stage
clinical development designed to provide effective long-term relief of pain
associated with peripheral neuropathies. The Company's product Ceplene^®, when
used concomitantly with low-dose interleukin-2 (IL-2) is intended as remission
maintenance therapy in the treatment of acute myeloid leukemia (AML) for adult
patients who are in their first complete remission. The Company sold all of
its rights to Ceplene^® in Europe and certain Pacific Rim countries and a
portion of its remaining Ceplene^® inventory to Meda AB. Ceplene^® is licensed
to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its
rights to Ceplene^® in all other countries, including countries in North and
South America. The Company has other oncology drug candidates in clinical
development that were discovered using in-house technology and have been shown
to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans,
anticipation, intent, contingency, goals, targets, future development and are
otherwise not statements of historical fact. These statements are based on our
current expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. Factors that may cause actual results or
developments to differ materially include: the risk that Ceplene^® will not
receive regulatory approval or marketing authorization in the United States or
Canada, the risk that Ceplene^® will not achieve significant commercial
success, the risks associated with the adequacy of our existing cash resources
and our ability to continue as a going concern, the risks associated with our
ability to continue to meet our obligations under our existing debt
agreements, the risk that Azixa™ will not receive regulatory approval or
achieve significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myrexis, the risk that clinical
trials for AmiKet™ or crolibulin^TM will not be successful, the risk that
AmiKet™ or crolibulin^TM will not receive regulatory approval or achieve
significant commercial success, the risk that we will not be able to find a
partner to help conduct the Phase III trials for AmiKet™ on attractive terms,
a timely basis or at all, the risk that our other product candidates that
appeared promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later-stage clinical trials, the
risk that we will not obtain approval to market any of our product candidates,
the risks associated with dependence upon key personnel, the risks associated
with reliance on collaborative partners and others for further clinical
trials, development, manufacturing and commercialization of our product
candidates; the cost, delays and uncertainties associated with our scientific
research, product development, clinical trials and regulatory approval
process; our history of operating losses since our inception; the highly
competitive nature of our business; risks associated with litigation; and
risks associated with our ability to protect our intellectual property. These
factors and other material risks are more fully discussed in our periodic
reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings
with the U.S. Securities and Exchange Commission. You are urged to carefully
review and consider the disclosures found in our filings which are available
at www.sec.gov or at www.epicept.com. You are cautioned not to place undue
reliance on any forward-looking statements, any of which could turn out to be
wrong due to inaccurate assumptions, unknown risks or uncertainties or other
risk factors.

*Azixa is a registered trademark of Myrexis, Inc.

EPCT-GEN

Contact:

EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
 
Press spacebar to pause and continue. Press esc to stop.